St Jude gets US nod to add V-V (ventricle to ventricle) timing in CRT-Ds (cardiac resynchronisation therapy devices):
This article was originally published in Clinica
The US FDA has given St Jude Medical approval to add V-V (ventricle to ventricle) timing to new models of its Epic HF and Atlas+ HF family of cardiac resynchronisation therapy devices (CRT-Ds). V-V timing refers to the delay between contraction of the left and right ventricles, compared with simultaneous pulses to both ventricles. St Jude's V-V timing allows physicians to adjust the delay between ventricular outputs, and choose which chamber is paced first. Patients who do not respond to simultaneous biventricular pacing systems may benefit from the sequential timing offered by V-V programmability, said the St Paul, Minnesota firm, which believes it is the first CRT-D supplier in the US to offer this expanded programmability.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.